• Almirall SA, of Barcelona, Spain, said it granted Invida Holdings Private Ltd., part of the Menarini Group, of Florence, Italy, the commercial rights for Aclidinium, a long-acting inhaled muscarinic antagonist, in Australia and New Zealand, for chronic obstructive pulmonary disorder.